Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer--Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial (European Urology)

In a randomised setting, intermediate- or high-risk prostate cancer patients treated with adjuvant chemotherapy with docetaxel following radical radiotherapy and androgen deprivation therapy (ADT) did not show improved biochemical disease-free survival compared with those who underwent radical radiotherapy and ADT alone. More adverse events occurred with the combined treatment, but there were fewer prostate-specific antigen relapses than were estimated to occur in both groups.